This BRAF activation in EGFR-mutant NSCLC seems to be exclusively reported in patients treated with osimertinib [8], which has become the SOC first-line treatment in patients suffering from an advanced-stage NSCLC harboring common exon 19 and 21 EGFR mutations. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.